KEMOTERAPİYE BAĞLI EKSTRAVAZASYON

Kaynaklar:

1-Lemmers NW, Gels ME, Sleijfer DT, Plukker JT, van der Graaf WT, de Langen ZJ, Droste JH, Koops HS, Hoekstra HJ. Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol. 1996;14:2916–2922. 

2-Froiland K. Extravasation injuries: implications for WOC nursing. J Wound Ostomy Continence Nurs. 2007;34:299–302.

3-Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15:858–862. 

4-Kretzschmar A, Pink D, Thuss-Patience P, Dörken B, Reichert P, Eckert R. Extravasations of oxaliplatin. J Clin Oncol. 2003;21:4068–4069. 

5- Polovich M, Olsen M, Le Febvre K (eds. ). Chemotherapy and biotherapy guidelines and recommendations for practice. 4th ed. Pittsburgh, Pennsylvania: Oncology Nursing Society; 2014. 

6-Coyle CE, Griffie J, Czaplewski LM. Eliminating extravasation events: a multidisciplinary approach. J Infus Nurs. 2014;37:157–164. 

7-Hadaway L. Infiltration and extravasation. Am J Nurs. 2007;107:64–72. [PubMed] [Google Scholar] 3. Cassagnol M, McBride A. Management of Chemotherapy Extravasations. US Pharm, 2009: 3-11 

8-El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A, Abbas J. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol. 2004;5:320–321. 

9-Chang PH, Wang MT, Chen YH, Chen YY, Wang CH. Docetaxel extravasation results in significantly delayed and relapsed skin injury: A case report. Oncol Lett. 2014;7:1497–1498.

10-Biffi R, Pozzi S, Agazzi A, Pace U, Floridi A, Cenciarelli S, Peveri V, Cocquio A, Andreoni B, Martinelli G. Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol. 2004;15:296–300. 

11-El Saghir NS, Otrock ZK. Docetaxel extravasation into the normal breast during breast cancer treatment. Anticancer Drugs. 2004;15:401–404.

12-Barbee MS, Owonikoko TK, Harvey RD. Taxanes: vesicants, irritants, or just irritating? Ther Adv Med Oncol. 2014;6:16–20. 

13-St Luke’s Cancer Alliance NH. Guidelines for Prevention and Management of Chemotherapy Extravasation, 2014: 1-18.